When is Dyania Health the better choice?

It published methods rather than claims, with peer reviewed real world evidence from a major academic health system where the platform screened across many hospitals. The clinician in the loop design was preserved inside the published study rather than described separately from it. Diversity was treated as a measured study endpoint rather than a marketing claim about equitable access.

When is Triomics the better choice?

It is oncology tuned rather than disease agnostic, which matters because decisive eligibility detail usually sits in pathology and biomarker text. Peer reviewed validation in a recognised digital medicine journal is the strongest evidence position in the trials category. Every match traces back to the pathology, biomarker and note that produced it, and the output lands where the oncology team already works.

Dyania Health vs Triomics

Last VerifiedAugust 4, 2026

Verdict

The two best evidenced chart reasoning platforms in clinical trials, and they published different things. Dyania published its methods and real world evidence from a major academic health system where the platform screened across many hospitals, keeping the clinician in the loop inside the study itself and treating diversity as a measured endpoint rather than a claim. Triomics published validation in a recognised digital medicine journal, is oncology tuned, and traces every match back to the pathology and biomarker that produced it, delivered where the oncology team already works. For a cancer centre, Triomics fits the specialty more tightly. For a health system that will have to defend how patients were screened, Dyania has already published what that process looks like in practice.

Select Dyania Health if

It published methods rather than claims, with peer reviewed real world evidence from a major academic health system where the platform screened across many hospitals.
The clinician in the loop design was preserved inside the published study rather than described separately from it.
Diversity was treated as a measured study endpoint rather than a marketing claim about equitable access.

Select Triomics if

It is oncology tuned rather than disease agnostic, which matters because decisive eligibility detail usually sits in pathology and biomarker text.
Peer reviewed validation in a recognised digital medicine journal is the strongest evidence position in the trials category.
Every match traces back to the pathology, biomarker and note that produced it, and the output lands where the oncology team already works.

Attribute Matrix

Side by Side

Axis	D Dyania Health	T Triomics
AI Centrality
Autonomy and Oversight Model
Model and Technology Transparency
Clinical and Operational Evidence
AI Safety and PHI Stewardship
HIPAA and BAA Posture
Security Certifications and Trust Center
FDA and Regulatory Status
AI Governance and Bias Disclosure
EHR and Interoperability Depth
Deployment Model and Data Residency
Commercial Transparency
Setting and Specialty Coverage

Keep Comparing

Related comparisons

Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.

Atropos Health vs Triomics→Deep 6 AI vs Dyania Health→Deep 6 AI vs Triomics→Dyania Health vs Mendel→Iterative Health vs Triomics→Mendel vs Triomics→Paradigm Health vs Triomics→Triomics vs xCures→

Disclosure

Both should be asked for the false negative rate on eligibility screening, which neither publishes and which is the only real measure of a matching system, since an eligible patient who never surfaced is invisible in every metric either reports. Both inherit documentation bias, so patients with thin or fragmented records match less often regardless of eligibility. Neither publishes a security attestation or trust centre, and neither publishes pricing.